Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Tuberculosis

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 90 articles: HTML format

Single Articles

June 2022
1. MARAIS BJ, Graham SM
   The Value of Chest Radiography in Tuberculosis Preventive Treatment (TPT) Screening in Children and Adolescents.
   Am J Respir Crit Care Med. 2022 Jun 2. doi: 10.1164/rccm.202205-1023.
   PubMed    
   
   
   May 2022
2. DOWDY DW
   Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin.
   Am J Respir Crit Care Med. 2022 May 25. doi: 10.1164/rccm.202204-0645.
   PubMed    
   
   
   
3. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
   The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis.
   Am J Respir Crit Care Med. 2022 May 24. doi: 10.1164/rccm.202202-0259.
   PubMed     Abstract available
   
   
   
4. DINKELE R, Gessner S, McKerry A, Leonard B, et al
   Aerosolization of Mycobacterium tuberculosis by Tidal Breathing.
   Am J Respir Crit Care Med. 2022 May 18. doi: 10.1164/rccm.202110-2378.
   PubMed     Abstract available
   
   
   
5. DE JAGER V, Gupte N, Nunes S, Barnes GL, et al
   Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
   Am J Respir Crit Care Med. 2022;205:1228-1235.
   PubMed     Abstract available
   
   
   
6. ESMAIL A, Oelofse S, Lombard C, Perumal R, et al
   An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
   Am J Respir Crit Care Med. 2022;205:1214-1227.
   PubMed     Abstract available
   
   
   April 2022
7. SHAKU MT, Bishai WR
   Mycobacterium tuberculosis: A Pathogen That Can Hold its Breath a Long Time.
   Am J Respir Crit Care Med. 2022 Apr 20. doi: 10.1164/rccm.202203-0432.
   PubMed    
   
   
   
8. BUCSAN AN, Veatch A, Singh DK, Akter S, et al
   Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
   Am J Respir Crit Care Med. 2022 Apr 12. doi: 10.1164/rccm.202112-2747.
   PubMed     Abstract available
   
   
   
9. PITTET LF, Fritschi N, Tebruegge M, Dutta B, et al
   Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants: A Post Hoc Analysis of a Randomized Controlled Trial.
   Am J Respir Crit Care Med. 2022;205:830-841.
   PubMed     Abstract available
   
   
   March 2022
10. LANGE C, Barry Iii CE, Horsburgh CR Jr
    Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
    Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393.
    PubMed    
    
    
    January 2022
11. SCHLUGER NW
    Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.
    Am J Respir Crit Care Med. 2022 Jan 31. doi: 10.1164/rccm.202112-2866.
    PubMed    
    
    
    
12. O'DONNELL M, Mathema B
    Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.
    Am J Respir Crit Care Med. 2022;205:149-151.
    PubMed    
    
    
    December 2021
13. KAUSHIK A, Ammerman NC, Tasneen R, Lachau-Durand S, et al
    Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy.
    Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541.
    PubMed     Abstract available
    
    
    
14. FENNELLY KP, Martinez L, Mandalakas AM
    Tuberculosis: First in Flight.
    Am J Respir Crit Care Med. 2021 Dec 14. doi: 10.1164/rccm.202111-2513.
    PubMed    
    
    
    
15. SHIMIZU T, Watanabe S, Murata A, Kasahara K, et al
    Bronchial Cast Hiding Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2021 Dec 3. doi: 10.1164/rccm.202105-1306.
    PubMed    
    
    
    
16. SCHLUGER NW
    Using Isoniazid More Safely and More Effectively: The Time Is Now.
    Am J Respir Crit Care Med. 2021;204:1248-1250.
    PubMed    
    
    
    November 2021
17. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
    Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
    Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
    PubMed     Abstract available
    
    
    
18. ADJOBIMEY M, Behr MA, Menzies D
    Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
    Am J Respir Crit Care Med. 2021;204:1013-1014.
    PubMed    
    
    
    October 2021
19. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
    Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
    PubMed     Abstract available
    
    
    
20. NOURSADEGHI M, Gupta RK
    New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
    PubMed    
    
    
    September 2021
21. MULENGA H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, et al
    Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Sep 14. doi: 10.1164/rccm.202103-0548.
    PubMed     Abstract available
    
    
    
22. DARTOIS V, Dick T
    A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?
    Am J Respir Crit Care Med. 2021;204:505-507.
    PubMed    
    
    
    August 2021
23. DAVIS JL, Checkley W
    Characterization of Air Pollution Exposures as Risk Factors for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Aug 30. doi: 10.1164/rccm.202107-1795.
    PubMed    
    
    
    
24. GAUSI K, Ignatius EH, Sun X, Kim S, et al
    A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
    Am J Respir Crit Care Med. 2021 Aug 17. doi: 10.1164/rccm.202103-0534.
    PubMed     Abstract available
    
    
    
25. MITNICK CD, Furin JJ, Hewison C
    The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202106-1516.
    PubMed    
    
    
    
26. VERMA R, Patil S, Zhang N, Moreira FMF, et al
    A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564.
    PubMed     Abstract available
    
    
    
27. IMPERIAL MZ, Phillips PPJ, Nahid P, Savic RM, et al
    Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117.
    PubMed     Abstract available
    
    
    
28. BLOUNT RJ, Phan H, Trinh T, Dang H, et al
    Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
    Am J Respir Crit Care Med. 2021 Aug 3. doi: 10.1164/rccm.202101-0136.
    PubMed     Abstract available
    
    
    June 2021
29. ROELENS M, Battista Migliori G, Rozanova L, Estill J, et al
    Evidence-based Definition for Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Jun 9. doi: 10.1164/rccm.202009-3527.
    PubMed     Abstract available
    
    
    May 2021
30. WELLS G, Glasgow JN, Nargan K, Lumamba K, et al
    microCT Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in 3D Granuloma Morphology.
    Am J Respir Crit Care Med. 2021 May 20. doi: 10.1164/rccm.202101-0032.
    PubMed     Abstract available
    
    
    April 2021
31. 
    Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    
    
    
    
32. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    
    
    
    March 2021
33. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available
    
    
    
34. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available
    
    
    
35. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    
    
    
    
36. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    
    
    
    
37. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    
    
    
    February 2021
38. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    
    
    
    January 2021
39. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available
    
    
    
40. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available
    
    
    December 2020
41. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    
    
    
    November 2020
42. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available
    
    
    September 2020
43. 
    Erratum: Lower Bacillus Calmette-Guerin Protection against Mycobacterium tuberculosis Infection after Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020;202:909-910.
    PubMed    
    
    
    
44. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    
    
    
    
45. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    
    
    
    August 2020
46. BURZYNSKI J, Keshavjee S
    Supporting a Comprehensive, International Approach to Global Tuberculosis Eradication is the Right Thing to Do.
    Am J Respir Crit Care Med. 2020 Aug 24. doi: 10.1164/rccm.202007-2976.
    PubMed    
    
    
    
47. O'DONNELL M, Mathema B
    Operational Research on the Treatment of Drug-resistant Tuberculosis: Exciting Results that Need to be Protected.
    Am J Respir Crit Care Med. 2020 Aug 21. doi: 10.1164/rccm.202007-2974.
    PubMed    
    
    
    
48. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    
    
    
    July 2020
49. SCHLUGER NW
    Prevention of Multidrug-resistant Tuberculosis in Close Contacts: Back to the Future?
    Am J Respir Crit Care Med. 2020 Jul 27. doi: 10.1164/rccm.202006-2488.
    PubMed    
    
    
    
50. MENZIES NA, Bellerose M, Testa C, Swartwood N, et al
    Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.
    Am J Respir Crit Care Med. 2020 Jul 9. doi: 10.1164/rccm.202003-0526.
    PubMed     Abstract available
    
    
    
51. PODANY AT
    Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
    Am J Respir Crit Care Med. 2020 Jul 7. doi: 10.1164/rccm.202006-2144.
    PubMed    
    
    
    
52. CUTLER T, Scales D, Levine W, Schluger N, et al
    A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jul 1. doi: 10.1164/rccm.202003-0828.
    PubMed    
    
    
    June 2020
53. RODRIGUEZ CA, Sy KTL, Mitnick CD, Franke MF, et al
    Time Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias.
    Am J Respir Crit Care Med. 2020 Jun 18. doi: 10.1164/rccm.202001-0220.
    PubMed    
    
    
    
54. HUANG CC, Becerra MC, Calderon R, Contreras C, et al
    Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jun 17. doi: 10.1164/rccm.201908-1576.
    PubMed     Abstract available
    
    
    
55. 
    Erratum: Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2020;201:1454.
    PubMed    
    
    
    
56. JAIN S, Kumar P, Goyal JP
    Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452.
    PubMed    
    
    
    
57. ZAR HJ
    Reply to Jain et al.: Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452-1453.
    PubMed    
    
    
    May 2020
58. SCHEUERMANN L, Pei G, Domaszewska T, Zyla J, et al
    Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis.
    Am J Respir Crit Care Med. 2020 May 18. doi: 10.1164/rccm.201910-2063.
    PubMed     Abstract available
    
    
    
59. HIBMA JE, Radtke KK, Dorman SE, Jindani A, et al
    Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489.
    PubMed     Abstract available
    
    
    
60. DAVIDS M, Pooran A, Hermann C, Mottay L, et al
    A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guerin.
    Am J Respir Crit Care Med. 2020;201:1277-1291.
    PubMed     Abstract available
    
    
    April 2020
61. DHEDA K, Davids M
    Latent Tuberculosis Infection-associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?
    Am J Respir Crit Care Med. 2020;201:895-898.
    PubMed    
    
    
    
62. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0855.
    PubMed    
    
    
    
63. SWINDELLS S, Hughes M, Chaisson RE
    Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0761.
    PubMed    
    
    
    March 2020
64. DOOLEY KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al
    Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
    PubMed    
    
    
    
65. DECROO T, de Jong BC, Piubello A, Souleymane MB, et al
    High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202001-0201.
    PubMed    
    
    
    February 2020
66. WASSERMAN S, Furin J
    Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
    Am J Respir Crit Care Med. 2020 Feb 20. doi: 10.1164/rccm.202002-0264.
    PubMed    
    
    
    
67. 
    Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2020;201:500-501.
    PubMed    
    
    
    
68. VERNON A, Bishai W
    Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
    Am J Respir Crit Care Med. 2020;201:405-406.
    PubMed    
    
    
    
69. ANDRES S, Merker M, Heyckendorf J, Kalsdorf B, et al
    Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon.
    Am J Respir Crit Care Med. 2020 Feb 13. doi: 10.1164/rccm.201909-1819.
    PubMed    
    
    
    January 2020
70. DE JAGER VR, Vanker N, van der Merwe L, van Brakel E, et al
    Optimising beta-lactams Against Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149.
    PubMed    
    
    
    
71. VERRALL AJ, Chaidir L, Ruesen C, Apriani L, et al
    Lower BCG Protection Against Mycobacterium tuberculosis Infection After Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020 Jan 8. doi: 10.1164/rccm.201912-2349.
    PubMed    
    
    
    
72. MCSHANE H
    Controlled Human Infection Models - Is it Really Feasible to Give People Tuberculosis?
    Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2408.
    PubMed    
    
    
    December 2019
73. GUPTA RK, Lipman M, Jackson C, Sitch A, et al
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0969.
    PubMed     Abstract available
    
    
    
74. ABUBAKAR I, Cobelens FG, Rangaka MX
    The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.
    Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258.
    PubMed    
    
    
    November 2019
75. NISHIZAWA S, Tobino K
    Asymptomatic Tuberculous Pleurisy Mimicking Mesothelioma.
    Am J Respir Crit Care Med. 2019 Nov 25. doi: 10.1164/rccm.201906-1223.
    PubMed    
    
    
    
76. NAHID P, Mase SR, Migliori GB, Sotgiu G, et al
    Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2019;200:e93-e142.
    PubMed     Abstract available
    
    
    
77. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed    
    
    
    
78. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606.
    PubMed     Abstract available
    
    
    
79. NARITA M, Sullivan Meissner J, Burzynski J
    Use of Modeling to Inform Tuberculosis Elimination Strategies.
    Am J Respir Crit Care Med. 2019 Nov 7. doi: 10.1164/rccm.201910-2061.
    PubMed    
    
    
    October 2019
80. TEZERA LB, Mansour S, Elkington P
    Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.
    Am J Respir Crit Care Med. 2019 Oct 28. doi: 10.1164/rccm.201908-1506.
    PubMed     Abstract available
    
    
    
81. FOREMAN TW, Bucsan AN, Mehra S, Peloquin C, et al
    Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2019 Oct 24. doi: 10.1164/rccm.201903-0646.
    PubMed     Abstract available
    
    
    
82. MENZIES NA, Parriott A, Shrestha S, Dowdy DW, et al
    Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289.
    PubMed     Abstract available
    
    
    
83. AUBRY A, Veziris N
    Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1072-1073.
    PubMed    
    
    
    
84. CHOI HW, Shin JH, Kee SJ, Kwon YS, et al
    Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1073-1074.
    PubMed    
    
    
    September 2019
85. SAGAR AS, Dodge DL, Salahuddin M, Warner MT, et al
    Pleural Diseases: Pleurodesis via Indwelling Pleural Catheter, Dasatinib-induced Pleural Effusion, and IL-27 in Tuberculosis Pleural Effusion.
    Am J Respir Crit Care Med. 2019;200:771-773.
    PubMed    
    
    
    March 2019
86. LEE HS, Kee SJ, Shin JH, Kwon YS, et al
    Xpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting.
    Am J Respir Crit Care Med. 2019;199:784-794.
    PubMed     Abstract available
    
    
    
87. YOON C, Semitala FC, Cattamanchi A
    Reply to Parker: Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:665.
    PubMed    
    
    
    
88. PARKER RA
    Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:664.
    PubMed    
    
    
    February 2019
89. GUPTA S, Krug S, Pokkali S, Leanderson T, et al
    Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
    Am J Respir Crit Care Med. 2019;199:386-389.
    PubMed    
    
    
    January 2019
90. SULIMAN S, Luabeya AKK, Geldenhuys H, Tameris M, et al
    Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Am J Respir Crit Care Med. 2019;199:220-231.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: